Navigation Links
Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012

177542Total assets 

$  110,134$  149,700Liabilities and stockholders' equity Current liabilities:Accounts payable and accrued expenses 

$   17,775$
4,277Deferred revenue, current portion 

3,4293,429Total current liabilities 

21,2047,706Deferred revenue, less current portion 

39,42942,000Other long-term liabilities 

140288Commitments and contingenciesStockholders' equity:Preferred stock, $.001 par value, 10,000,000 shares authorized at September 30, 2012 and December 31, 2011; noshares issued and outstanding atat September 30, 2012 and December 31, 2011--Common stock, $.001 par value, 300,000,000 sharesauthorized at September 30, 2012 and December 31, 2011;70,727,827 and 61,285,514 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively

7161Additional paid-in capital 

453,624446,357Accumulated other comprehensive income (loss)

15(2)Accumulated deficit

(404,349)(346,710)Total stockholders' equity 

49,36199,706Total liabilities and stockholders' equity 

$  110,134$  149,700 Orexigen Therapeutics, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Nine Months Ended September 30, September 30, 2012201120122011Revenues:Collaborative agreement 

2,571License revenue ---971Total revenues 

8578572,5713,542Operating expenses:Research and development 

25,8061,53945,42811,237General and administrative 

5,6513,90714,90515,870Total operating expenses 

31,4575,44660,33327,107Loss from operations 

(30,600)(4,589)(57,762)(23,565)Other income (expense):Interest income 

36912535Interest expense 

--(2)(221)Total other income (expense) <

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
11. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Post Your Comments:
(Date:10/9/2015)... , October 9, 2015 ... --> The report summarizes key ... overall status of the manufacturers making ... and direction for companies and individuals ... . --> ...
(Date:10/9/2015)... 9, 2015 Henry Schein , Inc. ... health care products and services to office-based dental, animal ... the Henry Schein Disaster Relief Hotline is open for ... financial issues as a result of the disastrous flooding ... number for all Henry Schein customers is ...
(Date:10/9/2015)... , Oct. 9, 2015   Lexicon Pharmaceuticals, Inc. ... TELESTAR Phase 3 clinical study of telotristat etiprate has been ... annual symposium to be held from October 15-17, in ... with patients who completed the randomized treatment portion of the ... a poster session. --> --> ...
Breaking Medicine Technology:
... WIRE)--Apr 26, 2007 - A new study ... of Child Neurology indicates,that a treatment from ... cerebral palsy improves their quality of life ... The findings of this Medtronic-sponsored study should,expand ...
... Effectiveness of Hypertension,Treatment Valsartan in Preventing Cardiovascular ... /Xinhua-PRNewswire/ -- The clinical,outcomes of the JIKEI ... the Jikei University School of Medicine, was ... The,Lancet. The study, involving more than 3,000 ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... Amada Senior ... opened its newest office in Maryland – its Bethesda location. Amada ... as a project management technology consultant to many of the largest construction firms ...
(Date:10/9/2015)... ... October 09, 2015 , ... BrightStar Care® of ... Cabarrus County Active Living and Parks for its outstanding commitment to volunteering with ... to consistently going above and beyond the call of duty, seniors on the ...
(Date:10/9/2015)... ... October 09, 2015 , ... Dignity Health named Dr. David C. Morro ... – Chandler–McQueen opening later this month. The new facility is licensed under ... West Valley. , “Dr. Morro is an excellent leader and will ensure our ...
(Date:10/9/2015)... ... 2015 , ... When the producers of the popular ‘Ask This Old House’ ... Hollywood, CA, they turned to a trusted resource in Tamarack Technologies. , “Our HV ... because of our successful past experience with the show they enlisted our help,” said ...
(Date:10/9/2015)... ... , ... Bag Tags Inc. will provide custom bag tags, ... the annual IRONMAN World Championship in Kailua-Kona, Hawaii, this Saturday, October 10. ... place in Hawaii every year since 1978. , As part of its ongoing ...
Breaking Medicine News(10 mins):
... , LOS ANGELES, Oct. 9 Torrid,s 2009 House of ... for the retailer known as the destination for young women,s ... the courtyard at the Fashion Institute of Design and Merchandising ... who work to motivate women and to support the National ...
... cancer epidemic, researchers say , FRIDAY, Oct. 9 (HealthDay News) ... increase in cases of a rare type of head and ... -- a tumor that grows behind the nose and at ... about one of every 100,000 people in the United States. ...
... of Hematology (ASH) is proud to announce the ... which builds hematologic capacity in developing countries. Through ... countries receive valuable clinical, laboratory, or technological training ... under the mentorship of an ASH member anywhere ...
... ... as CMS-mandated Home Health Agency Satisfaction Reporting Set to Begin , , ... South Bend, IN (Vocus) October ... country, and a new report released today finds an upward trend in overall home ...
... fight treatment-related bone loss, researchers say , FRIDAY, Oct. 9 ... of vitamin D, which could lead to weaker bones and ... doses of vitamin D for them. , "Vitamin D is ... have accelerated bone loss due to the nature of hormone ...
... ... 19, 2009 in San Diego, CA., , ... Horsham, PA (Vocus) October 8, 2009 -- The Drug Information Association (DIA) ... 2009 in San Diego, CA., , , , ,Electronic CTD is poised to become the ...
Cached Medicine News:
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Silicone Flat Hubless Drains...
Bard® Channel Drain...
Used to negotiate spiral folds of the cystic duct and the lumen of the common duct. TFE coating reduces surface tension. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: